Abbvie Share Price Today
(NASDAQ: ABBV)

Name: Abbvie Share Price Today (NASDAQ: ABBV) - Abbvie Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Abbvie share price is $202.08 & ₹17,525.59 as on 22 Feb 2025, 2.30 'hrs' IST

$202.08

▲

1.2

(0.6%)

Market is closed - opens 8 PM, 24 Feb 2025

View live Abbvie share price in Dollar and Rupees. Guide to invest in Abbvie stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Abbvie, along with analyst recommendations, forecasts, and comprehensive financials.

Abbvie share price movements

Today's Low: $200.02
Today's High: $203.97
$202.08
1.02%
Downside
Day's Volatility :1.94%
Upside
0.93%
52 Weeks Low: $153.58
52 Weeks High: $207.32
$202.08
24.0%
Downside
52 Weeks Volatility :25.92%
Upside
2.53%

Abbvie (ABBV) Returns

Period	Abbvie Inc	Sector (Health Care)	S&P500
3 Months	13.45%	2.2%	2.8%
6 Months	1.74%	-4.8%	8.8%
1 Year	12.8%	1.2%	22.8%
3 Years	36.88%	15.5%	40.7%

Abbvie (ABBV) Key Statistics

in dollars & INR

Previous Close	$200.88
Open	$200.32
Today's High	$203.97
Today's Low	$200.02
Market Capitalization	$348.4B
Today's Volume	$4.6M
52 Week High	$207.32
52 Week Low	$153.58
Revenue TTM	$56.3B
EBITDA	$26.2B
Earnings Per Share (EPS)	$2.39
PE Ratio	82.57
Dividend Yield	3.32%
Profit Margin	7.59%
Quarterly Earnings Growth YOY	-0.12%
Return On Equity TTM	62.29%

How to invest in Abbvie Stock (ABBV) from India?

It is very easy for Indian residents to invest directly in Abbvie from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Abbvie stock in both Indian Rupees (INR) and US Dollars (USD). Search for Abbvie or ABBV on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Abbvie or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Abbvie shares which would translate to 0.004 fractional shares of Abbvie as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Abbvie, in just a few clicks!

Returns in Abbvie (ABBV) for Indian investors in Rupees

The Abbvie stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Abbvie investment value today

Current value as on today

₹1,18,980

Returns

₹18,980

(+18.98%)

Returns from Abbvie Stock

₹14,331 (+14.33%)

Dollar Returns

₹4,649 (+4.65%)

Indian investors sentiment towards Abbvie (ABBV)

71.0%

Period: Jan 22, 2025 to Feb 21, 2025. Change in 30 Days versus previous period

Investment in Abbvie Shares from India has grown by 71.0% over the past 30 days, indicating increased transactional activity.

118%

Period: Jan 22, 2025 to Feb 21, 2025. Change in 30 Days versus previous period

Search interest for Abbvie Stock from India on INDmoney has increased by 118% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Abbvie Stock (ABBV Ticker)

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	15244	101.07	0.63%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	2664	575.98	2.78%

Global Institutional Holdings in Abbvie

Vanguard Group Inc
9.80%
BlackRock Inc
7.70%
JPMorgan Chase & Co
5.92%
State Street Corp
4.48%
Morgan Stanley - Brokerage Accounts
2.19%
Geode Capital Management, LLC
2.05%

Analyst Recommendation on Abbvie

Buy

65%Buy

34%Hold

0%Sell

Based on 35 Wall street analysts offering stock ratings for Abbvie(by analysts ranked 0 to 5 stars)

Based on 35 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Abbvie Stock (ABBV)

What analysts predicted

Upside of 1.39%

Target:

$204.90

Current:

$202.08

Insights on Abbvie Stock (Ticker Symbol: ABBV)

Price Movement
In the last 1 month, ABBV stock has moved up by 16.4%
Increasing Revenue
AbbVie Inc has shown positive performance in its revenue over the last two quarters. The revenue increased from $14.46 billion to $15.10 billion, marking an average growth of 4.3% per quarter.
Decreasing Net Profit
Abbvie Inc has faced a significant decline in its profits over the last two quarters. The net profit dropped from $1.56 billion to negative $22 million. This represents an average decrease of 101.4% per quarter, indicating a substantial downturn in the company's financial performance.
ABBV vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 17.1% return, outperforming this stock by 2.4%
ABBV vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 263.3% return, outperforming this stock by 223.8%
Price to Sales
AbbVie Inc. has a Price-to-Sales Ratio of 6.3, meaning that investors are willing to pay $6.3 for every $1 of sales the company generates. In comparison, Eli Lilly And Company has a much higher Price-to-Sales Ratio of 17.5, indicating that investors are willing to pay significantly more for each dollar of sales from Eli Lilly.

ABBV Abbvie Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$33.3B	↑ 1.57%
Net Income	$7.9B	↑ 38.6%
Net Profit Margin	23.69%	↑ 6.33%

	FY20	Y/Y Change
Revenue	$45.8B	↑ 37.69%
Net Income	$4.6B	↓ 41.44%
Net Profit Margin	10.08%	↓ 13.61%

	FY21	Y/Y Change
Revenue	$56.2B	↑ 22.69%
Net Income	$11.5B	↑ 150.04%
Net Profit Margin	20.54%	↑ 10.46%

	FY22	Y/Y Change
Revenue	$58.1B	↑ 3.3%
Net Income	$11.8B	↑ 2.55%
Net Profit Margin	20.39%	↓ 0.15%

	FY23	Y/Y Change
Revenue	$54.3B	↓ 6.44%
Net Income	$4.9B	↓ 58.91%
Net Profit Margin	8.95%	↓ 11.44%

	FY24	Y/Y Change
Revenue	$56.3B	↑ 3.71%
Net Income	$4.3B	↓ 12.03%
Net Profit Margin	7.59%	↓ 1.36%

	Q3 FY23	Q/Q Change
Revenue	$13.9B	↑ 0.45%
Net Income	$1.8B	↓ 12.15%
Net Profit Margin	12.77%	↓ 1.83%

	Q4 FY23	Q/Q Change
Revenue	$14.3B	↑ 2.69%
Net Income	$822.0M	↓ 53.77%
Net Profit Margin	5.75%	↓ 7.02%

	Q1 FY24	Q/Q Change
Revenue	$12.3B	↓ 13.92%
Net Income	$1.4B	↑ 66.55%
Net Profit Margin	11.12%	↑ 5.37%

	Q2 FY24	Q/Q Change
Revenue	$14.5B	↑ 17.48%
Net Income	$1.4B	↑ 0.07%
Net Profit Margin	9.47%	↓ 1.65%

	Q3 FY24	Q/Q Change
Revenue	$14.5B	↓ 0.01%
Net Income	$1.6B	↑ 13.94%
Net Profit Margin	10.8%	↑ 1.33%

	Q4 FY24	Q/Q Change
Revenue	$15.1B	↑ 4.44%
Net Income	$-22.0M	↓ 101.41%
Net Profit Margin	-0.15%	↓ 10.95%

	FY19	Y/Y Change
Profit	$25.8B	↑ 3.16%

	FY20	Y/Y Change
Profit	$30.4B	↑ 17.77%

	FY21	Y/Y Change
Profit	$38.8B	↑ 27.4%

	FY22	Y/Y Change
Profit	$40.6B	↑ 4.87%

	FY23	Y/Y Change
Profit	$33.9B	↓ 16.58%

	FY24	Y/Y Change
Profit	$39.4B	↑ 16.3%

	Q3 FY23	Q/Q Change
Profit	$7.4B	↓ 22.68%

	Q4 FY23	Q/Q Change
Profit	$11.9B	↑ 60.1%

	Q1 FY24	Q/Q Change
Profit	$8.2B	↓ 30.94%

	Q2 FY24	Q/Q Change
Profit	$12.3B	↑ 49.32%

	Q3 FY24	Q/Q Change
Profit	$10.2B	↓ 16.59%

	Q4 FY24	Q/Q Change
Profit	$10.7B	↑ 4.47%

	FY19	Y/Y Change
Operating Cash Flow	$13.3B	↓ 0.77%
Investing Cash Flow	$596.0M	↓ 159.24%
Financing Cash Flow	$18.7B	↓ 229.95%

	FY20	Y/Y Change
Operating Cash Flow	$17.6B	↑ 32.0%
Investing Cash Flow	$-37.6B	↓ 6401.51%
Financing Cash Flow	$-11.5B	↓ 161.48%

	FY21	Y/Y Change
Operating Cash Flow	$22.8B	↑ 29.5%
Investing Cash Flow	$-2.3B	↓ 93.76%
Financing Cash Flow	$-19.0B	↑ 65.54%

	FY22	Y/Y Change
Operating Cash Flow	$24.9B	↑ 9.51%
Investing Cash Flow	$-623.0M	↓ 73.42%
Financing Cash Flow	$-24.8B	↑ 30.27%

	FY23	Y/Y Change
Operating Cash Flow	$22.8B	↓ 8.44%
Investing Cash Flow	$-2.0B	↑ 222.47%
Financing Cash Flow	$-17.2B	↓ 30.56%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$7.6B	↑ 19.86%
Investing Cash Flow	$-369.0M	↑ 8.21%
Financing Cash Flow	$-2.7B	↓ 32.12%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$4.8B	↓ 37.25%
Investing Cash Flow	$-800.0M	↑ 116.8%
Financing Cash Flow	$-4.4B	↑ 67.19%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$4.0B	↓ 15.0%
Investing Cash Flow	$-9.6B	↑ 1098.5%
Financing Cash Flow	$10.8B	↓ 343.18%

Abbvie Technicals Summary

Sell

Neutral

Buy

Abbvie is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Abbvie (ABBV) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Abbvie Inc	17.7%	1.74%	12.8%	36.88%	115.68%
Eli Lilly And Company	13.9%	-8.14%	13.46%	266.38%	532.01%
Johnson & Johnson	8.89%	-2.99%	-1.33%	-0.96%	9.44%
Merck & Co. Inc.	-9.26%	-24.59%	-32.27%	15.61%	7.81%
Novo Nordisk A/s	3.26%	-38.11%	-32.17%	71.46%	173.3%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Abbvie Inc	82.57	82.57	2.63	12.26	0.62	0.08	0.03	1.88
Eli Lilly And Company	74.56	74.56	0.87	23.1	0.84	0.14	0.01	15.83
Johnson & Johnson	27.27	27.27	1.0	10.55	0.2	0.08	0.03	29.7
Merck & Co. Inc.	12.7	12.7	0.07	8.99	0.42	0.11	0.04	17.58
Novo Nordisk A/s	26.23	26.23	1.2	0.0	0.81	0.22	0.02	32.31

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Abbvie Inc	Buy	$348.4B	115.68%	82.57	7.59%
Eli Lilly And Company	Buy	$784.2B	532.01%	74.56	23.51%
Johnson & Johnson	Buy	$380.1B	9.44%	27.27	15.84%
Merck & Co. Inc.	Buy	$216.5B	7.81%	12.7	26.67%
Novo Nordisk A/s	Buy	$366.2B	173.3%	26.23	34.78%

Abbvie Dividend announcements

Abbvie Dividends June, 2025
In the quarter ending June,2025. Abbvie has declared dividend of $1.64
Read More

About Abbvie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Organization	Abbvie
Employees	55000
CEO	Mr. Richard A. Gonzalez
Industry	Health Technology

Management People of Abbvie

Name	Title
Mr. Richard A. Gonzalez	Executive Chairman
Dr. Azita Saleki-Gerhardt Ph.D.	Executive VP & COO
Ms. Elizabeth Shea	Senior Vice President of Investor Relations
Mr. Sanjay Narayan	Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal
Mr. Timothy J. Richmond	Executive VP & Chief Human Resources Officer
Ms. Tracie Haas	Senior Vice President of Corporate Affairs
Mr. Greg Miley	Senior Vice President of Government Affairs
Ms. Assil Omar	VP & Chief Equity Officer
Dr. Latif Akintade M.D.	Senior Vice President of Medical Affairs & Health Economics Outcomes Research

Important FAQs about investing in ABBV Stock from India :

What is Abbvie share price today?

Abbvie share price today stands at $202.08, Open: $200.32 ; Previous Close: $200.88 ; High: $203.97 ; Low: $200.02 ; 52 Week High: $207.32 ; 52 Week Low: $153.58.

The stock opens at $200.32, after a previous close of $200.88. The stock reached a daily high of $203.97 and a low of $200.02, with a 52-week high of $207.32 and a 52-week low of $153.58.

Can Indians buy Abbvie shares?

Yes, Indians can invest in the Abbvie (ABBV) from India.

With INDmoney, you can buy Abbvie at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Abbvie at zero transaction cost.

How can I buy Abbvie shares from India?

It is very easy to buy Abbvie from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Abbvie (ABBV) be purchased?

Yes, you can buy fractional shares of Abbvie with INDmoney app.

What are the documents required to start investing in Abbvie stocks?

To start investing in Abbvie, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.